Similar articles for PMID: 18570163

Year	Number of Results
1999	1
2002	1
2003	1
2004	5
2005	4
2006	2
2007	7
2008	7
2009	4
2010	3
2011	7
2012	3
2013	6
2014	2
2019	1
2024	0

1

Role of pharmacodiagnostic of CYP2C9 variants in the optimization of warfarin therapy in Malaysia: a 6-month follow-up study.

Ngow H, Teh LK, Langmia IM, Lee WL, Harun R, Ismail R, Salleh MZ. Ngow H, et al. Xenobiotica. 2008 Jun;38(6):641-51. doi: 10.1080/00498250801999087. Xenobiotica. 2008. PMID: 18570163

2

CYP2C9 polymorphism: prevalence in healthy and warfarin-treated Malay and Chinese in Malaysia.

Ngow HA, Wan Khairina WM, Teh LK, Lee WL, Harun R, Ismail R, Salleh MZ. Ngow HA, et al. Singapore Med J. 2009 May;50(5):490-3. Singapore Med J. 2009. PMID: 19495518 Free article.

3

Association between the CYP2C9 polymorphism and the drug metabolism phenotype.

Topić E, Stefanović M, Samardzija M. Topić E, et al. Clin Chem Lab Med. 2004 Jan;42(1):72-8. doi: 10.1515/CCLM.2004.014. Clin Chem Lab Med. 2004. PMID: 15061384

4

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.

Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE. Higashi MK, et al. JAMA. 2002 Apr 3;287(13):1690-8. doi: 10.1001/jama.287.13.1690. JAMA. 2002. PMID: 11926893

5

Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype.

Voora D, Eby C, Linder MW, Milligan PE, Bukaveckas BL, McLeod HL, Maloney W, Clohisy J, Burnett RS, Grosso L, Gatchel SK, Gage BF. Voora D, et al. Thromb Haemost. 2005 Apr;93(4):700-5. doi: 10.1160/TH04-08-0542. Thromb Haemost. 2005. PMID: 15841315

6

Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.

Miao L, Yang J, Huang C, Shen Z. Miao L, et al. Eur J Clin Pharmacol. 2007 Dec;63(12):1135-41. doi: 10.1007/s00228-007-0381-6. Epub 2007 Sep 27. Eur J Clin Pharmacol. 2007. PMID: 17899045 Clinical Trial.

7

An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.

Meckley LM, Wittkowsky AK, Rieder MJ, Rettie AE, Veenstra DL. Meckley LM, et al. Thromb Haemost. 2008 Aug;100(2):229-39. Thromb Haemost. 2008. PMID: 18690342

8

The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes.

Tomek A, Maťoška V, Kolářová T, Neumann J, Srámek M, Sarbochová I, Táborský L, Bojar M, Goetz P, Serebruany VL. Tomek A, et al. Cardiology. 2013;125(3):182-91. doi: 10.1159/000350407. Epub 2013 Jun 12. Cardiology. 2013. PMID: 23774101

9

Extremely low warfarin dose in patients with genotypes of CYP2C9*3/*3 and VKORC1-1639A/A.

Gao L, He L, Luo J, Xu B, Yang J, Zhang YX, Yang T, Li K, Tian JW, Wang HJ, Zhao YS, Lu CY, Zhang WZ, Yin T. Gao L, et al. Chin Med J (Engl). 2011 Sep;124(17):2767-70. Chin Med J (Engl). 2011. PMID: 22040439

10

Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.

Carlquist JF, Horne BD, Muhlestein JB, Lappé DL, Whiting BM, Kolek MJ, Clarke JL, James BC, Anderson JL. Carlquist JF, et al. J Thromb Thrombolysis. 2006 Dec;22(3):191-7. doi: 10.1007/s11239-006-9030-7. J Thromb Thrombolysis. 2006. PMID: 17111199

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

50 results

Results by year